It's uncertain whether the Biden administration proposal to cover obesity drugs in Medicare and Medicaid will survive ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

Millions more senior citizens and lower-income Americans could obtain coverage for costly anti-obesity drugs under a proposal ...

The Biden Administration released plans for a new rule that would require Medicare and Medicaid to cover anti-obesity ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body ...

The proposed rule could give millions of Americans access to the new drugs; it will also put pressure on the incoming Trump administration.

The Biden administration is looking to expand access to anti-obesity GLP-1 drugs like Ozempic and Wegovy for people who have ...

U.S. President Joe Biden on Tuesday proposed expanding coverage of anti-obesity drugs, like Novo Nordisk's Wegovy, for more ...

More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the ...

The Biden administration has proposed a new rule to “significantly” expand coverage of anti-obesity medications for Americans ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.